Atlantic Healthcare confirms alicaforsen targets TLR-9, providing a second mechanism of action to treat new and existing inflammatory indications
Patent applications filed based on novel discovery, which may provide…
Atlantic Healthcare to present at BIO CEO & Investor Conference 2017
Leadership Team available for meetings in New York, February 13-14 and 21…
Atlantic Healthcare receives FDA agreement to initiate rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
FDA to accept sections of the regulatory application ahead of final Phase 3…
Atlantic Healthcare granted U.S. patent extending IP cover of alicaforsen in the treatment of inflammatory bowel disease
Patent covers use of antisense oligonucleotides to treat rectal stump…
Atlantic Healthcare a finalist for the pharma industry 2016 Scrip Awards
Cambridge, UK; September 29, 2016. Atlantic Healthcare plc ("Atlantic…
Atlantic Healthcare progresses manufacturing arrangements for globalsupply of alicaforsen
Atlantic Healthcare appoints Mike Webb as Vice President of Manufacturing and…
Atlantic Healthcare closes $24 million financing with founders of SalixPharmaceuticals and Clinigen Group, and LDC
Investment secures funds to complete pivotal Phase 3 trial of alicaforsen in…
Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treatInflammatory Bowel Disease Pouchitis
Study of fast-tracked and orphan designated alicaforsen is the largest ever in…